Equities research analysts expect athenahealth, Inc. (NASDAQ:ATHN) to post $298.48 million in sales for the current fiscal quarter, Zacks reports. Twelve analysts have issued estimates for athenahealth’s earnings. The highest sales estimate is $306.25 million and the lowest is $291.00 million. athenahealth reported sales of $261.94 million in the same quarter last year, which indicates a positive year over year growth rate of 13.9%. The company is scheduled to announce its next earnings results after the market closes on Thursday, July 20th.
According to Zacks, analysts expect that athenahealth will report full year sales of $298.48 million for the current financial year, with estimates ranging from $1.20 billion to $1.32 billion. For the next fiscal year, analysts expect that the business will report sales of $1.39 billion per share, with estimates ranging from $1.34 billion to $1.45 billion. Zacks Investment Research’s sales calculations are a mean average based on a survey of sell-side analysts that cover athenahealth.
athenahealth (NASDAQ:ATHN) last posted its quarterly earnings results on Thursday, April 27th. The health services provider reported $0.10 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.11 by $0.01. athenahealth had a return on equity of 5.93% and a net margin of 1.84%. The business had revenue of $285.40 million for the quarter, compared to analysts’ expectations of $296.49 million. During the same period in the prior year, the business posted $0.34 earnings per share. The business’s quarterly revenue was up 11.4% compared to the same quarter last year.
A number of equities research analysts have weighed in on ATHN shares. UBS Group AG set a $123.00 price objective on athenahealth and gave the company a “buy” rating in a research note on Monday, May 1st. Citigroup Inc set a $128.00 price target on athenahealth and gave the stock a “buy” rating in a research note on Monday, May 1st. Cantor Fitzgerald restated a “buy” rating and set a $118.00 price target (down previously from $135.00) on shares of athenahealth in a research note on Thursday, April 27th. Robert W. Baird set a $140.00 price target on athenahealth and gave the stock a “buy” rating in a research note on Thursday, May 18th. Finally, Dougherty & Co upped their price target on athenahealth from $123.00 to $148.00 and gave the stock a “buy” rating in a research note on Tuesday, May 23rd. Two investment analysts have rated the stock with a sell rating, twelve have given a hold rating and twelve have issued a buy rating to the stock. The stock has an average rating of “Hold” and a consensus target price of $139.81.
TRADEMARK VIOLATION NOTICE: This news story was originally posted by StockNewsTimes and is the sole property of of StockNewsTimes. If you are viewing this news story on another domain, it was illegally stolen and republished in violation of U.S. and international copyright and trademark legislation. The original version of this news story can be accessed at https://stocknewstimes.com/2017/08/13/298-48-million-in-sales-expected-for-athenahealth-inc-athn-this-quarter-updated-updated-updated.html.
In other news, CEO Jonathan Bush sold 4,000 shares of the firm’s stock in a transaction dated Monday, July 3rd. The stock was sold at an average price of $140.52, for a total value of $562,080.00. Following the transaction, the chief executive officer now directly owns 319,807 shares in the company, valued at approximately $44,939,279.64. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, SVP Bradford Kyle Armbrester sold 2,431 shares of the firm’s stock in a transaction dated Thursday, May 18th. The stock was sold at an average price of $130.00, for a total value of $316,030.00. The disclosure for this sale can be found here. Over the last three months, insiders sold 25,383 shares of company stock worth $3,286,932. 3.20% of the stock is owned by corporate insiders.
Institutional investors have recently added to or reduced their stakes in the company. Cribstone Capital Management LLC increased its position in athenahealth by 3.3% in the second quarter. Cribstone Capital Management LLC now owns 14,186 shares of the health services provider’s stock worth $1,994,000 after buying an additional 452 shares during the period. CrestPoint Capital Management LLC purchased a new position in athenahealth during the second quarter worth approximately $337,000. Clearbridge Investments LLC increased its position in athenahealth by 61.8% in the first quarter. Clearbridge Investments LLC now owns 908,505 shares of the health services provider’s stock worth $102,379,000 after buying an additional 347,133 shares during the period. FNY Partners Fund LP increased its position in athenahealth by 1,900.0% in the first quarter. FNY Partners Fund LP now owns 1,000 shares of the health services provider’s stock worth $112,000 after buying an additional 950 shares during the period. Finally, Credit Suisse AG increased its position in athenahealth by 404.5% in the first quarter. Credit Suisse AG now owns 300,420 shares of the health services provider’s stock worth $33,854,000 after buying an additional 240,876 shares during the period.
athenahealth (NASDAQ:ATHN) traded up 0.86% during trading on Friday, reaching $143.19. 465,559 shares of the company’s stock were exchanged. athenahealth has a 52 week low of $90.11 and a 52 week high of $149.55. The stock has a 50-day moving average of $135.17 and a 200-day moving average of $119.14. The stock has a market capitalization of $5.70 billion, a PE ratio of 281.87 and a beta of 1.79.
athenahealth Company Profile
athenahealth, Inc provides network-based medical record, revenue cycle, patient engagement, care coordination and population health services. The Company also offers Epocrates and other point-of-care mobile applications. The Company delivers majority of its service offerings through a single instance of cloud-based software, athenaNet.
Get a free copy of the Zacks research report on athenahealth (ATHN)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for athenahealth Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for athenahealth Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
